Immune Design reports Phase I OS data for CMB305 in STS

In March, Immune Design Corp. (NASDAQ:IMDZ) reported data from 25 patients with cancer/testis antigen 1B (NY-ESO-1; CTAG1B)-positive soft tissue sarcoma (STS)

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE